Lexaria Bioscience (NASDAQ:LEXX) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Lexaria Bioscience (NASDAQ:LEXX) announced its quarterly earnings data on Monday. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01, Zacks reports. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.14 million. Lexaria Bioscience had a negative net margin of 1,473.04% and a negative return on equity of 88.88%.

Lexaria Bioscience Price Performance

LEXX stock opened at $1.41 on Tuesday. The company has a market capitalization of $24.75 million, a P/E ratio of -2.82 and a beta of 0.86. Lexaria Bioscience has a 12 month low of $1.15 and a 12 month high of $4.44. The firm’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $2.04.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their price target on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, January 24th.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.